Orasis Expands QLOSI Access as Refills Reach 49%
PONTE VEDRA, Fla., July 21, 2026 Orasis Pharmaceuticals has announced the expansion of patient access programs for QLOSIĀ® (pilocarpine...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
PONTE VEDRA, Fla., July 21, 2026 Orasis Pharmaceuticals has announced the expansion of patient access programs for QLOSIĀ® (pilocarpine...
MENLO PARK, Calif., July 20, 2026 BillionToOne has appointed renowned physician-scientist Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology,...
KIGALI, Rwanda, July 20, 2026 Akagera Medicines, Inc. has announced positive first-in-human Phase 1 results for AKG-100, its investigational...
